T2DM
Conditions
Interventions
Conventional comprehensive treatment group:None
Liraglutide treatment group:None
combined probiotics treatment group:None
Sponsors
Yunnan First People's Hospital
Eligibility
Sex/Gender
All
Age
20 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion Criteria 1. Meeting the diagnostic criteria for T2DM as specified in the *Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition)*; 2. Having dyslipidemia (meeting the diagnostic criteria in the *Guidelines for the Prevention and Treatment of Adult Dyslipidemia in China (2016 Revised Edition)*, i.e., total cholesterol >= 5.18 mmol/L, or triglycerides >= 1.69 mmol/L, or low-density lipoprotein cholesterol >= 3.39 mmol/L, or high-density lipoprotein cholesterol = 20 years; 4. Having complete clinical data, with accessible baseline and follow-up data on diagnosis and treatment for at least 6 months; 5. The patient or their family members having signed an informed consent form for the use of data in this study (re-authorization for the use of retrospective data).
Exclusion criteria
Exclusion criteria: Exclusion criteria 1. Patients with combined severe dysfunction or advanced lesions of heart, brain, liver, kidney and other organs (such as heart failure with NYHA class ?-?, decompensated cirrhosis, renal failure requiring dialysis, etc.); 2. Patients with other severe metabolic diseases (such as Cushing's syndrome, acromegaly, etc.) or autoimmune diseases; 3. Patients with a history of mental illness or cognitive impairment who cannot cooperate with routine diagnosis and treatment; 4. Patients who have long-term used drugs that may significantly affect the activity of probiotics or intestinal flora (such as broad-spectrum antibiotics, bismuth agents, etc.) during the observation period, and whose impact cannot be evaluated; 5. Patients with severely missing clinical data that cannot be used for statistical analysis; 6. Patients with other diseases that may affect metabolism or intestinal flora, such as malignant tumors and acute stage of infectious diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| gut microbiota; | — |
Countries
China
Contacts
Public ContactXu Ning
Yunnan First People's Hospital
Outcome results
None listed